Cargando…

The effect of 3-week tamoxifen treatment on oestrogen receptor levels in primary breast tumours: a flow cytometric study.

The effect of 3-week, preoperative tamoxifen treatment on oestrogen receptor (ER) levels, expressed by primary breast tumours, was examined. Patients (age-matched) with breast cancer, confirmed by fine-needle aspiration, were either treated with 20 mg ml(-1) oral tamoxifen per day or received no med...

Descripción completa

Detalles Bibliográficos
Autores principales: Brotherick, I., Browell, D. A., Shenton, B. K., Egan, M., Cunliffe, W. J., Webb, L. A., Lunt, L. G., Young, J. R., Higgs, M. J.
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 1998
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2150047/
https://www.ncbi.nlm.nih.gov/pubmed/9635844
_version_ 1782144562852003840
author Brotherick, I.
Browell, D. A.
Shenton, B. K.
Egan, M.
Cunliffe, W. J.
Webb, L. A.
Lunt, L. G.
Young, J. R.
Higgs, M. J.
author_facet Brotherick, I.
Browell, D. A.
Shenton, B. K.
Egan, M.
Cunliffe, W. J.
Webb, L. A.
Lunt, L. G.
Young, J. R.
Higgs, M. J.
author_sort Brotherick, I.
collection PubMed
description The effect of 3-week, preoperative tamoxifen treatment on oestrogen receptor (ER) levels, expressed by primary breast tumours, was examined. Patients (age-matched) with breast cancer, confirmed by fine-needle aspiration, were either treated with 20 mg ml(-1) oral tamoxifen per day or received no medication in the 3-week interval between assessment and surgery. Quantification of ER using flow cytometry was performed on the surgically removed tumour samples from tamoxifen-treated (n = 40) and control (n = 38, untreated) patient groups. The tumours were mechanically disaggregated, and saponin treatment rendered these cells permeable to antibodies. Using dual-parameter labelling with a FITC-conjugated antibody (NCL-5D3) directed against cytokeratin 8/18/19 and a biotinylated antibody (DAKO-ER 1D5) directed against the oestrogen receptor, ER quantification was determined on a number of receptors per cell basis. Using QC quantum bead standards, ER levels in the epithelial cell population, the non-epithelial cell population and the whole-cell population (ER+) were calculated. ER levels were significantly lower in the total cell population than tamoxifen-treated patients (P = 0.002) when compared with the control (untreated) group. By using a gating procedure using 5D3 antibody positivity, a significantly lower level was detected on examining the cytokeratin-positive population alone (P = 0.006). Using a complementary gating technique, ER levels were quantified in the cytokeratin-negative cell population. Examination of this group of cells showed no significant difference between the levels of oestrogen receptor found in the tamoxifen-treated and untreated groups (P = 0.4). We have demonstrated that ER levels can be monitored by flow cytometry. ER levels in patients treated with tamoxifen 3 weeks before operation are significantly lower than in a comparative group of patients who received no drug. Furthermore, the most significant difference in receptor levels is seen by quantification of total ER levels expressed by all the tissue.
format Text
id pubmed-2150047
institution National Center for Biotechnology Information
language English
publishDate 1998
publisher Nature Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-21500472009-09-10 The effect of 3-week tamoxifen treatment on oestrogen receptor levels in primary breast tumours: a flow cytometric study. Brotherick, I. Browell, D. A. Shenton, B. K. Egan, M. Cunliffe, W. J. Webb, L. A. Lunt, L. G. Young, J. R. Higgs, M. J. Br J Cancer Research Article The effect of 3-week, preoperative tamoxifen treatment on oestrogen receptor (ER) levels, expressed by primary breast tumours, was examined. Patients (age-matched) with breast cancer, confirmed by fine-needle aspiration, were either treated with 20 mg ml(-1) oral tamoxifen per day or received no medication in the 3-week interval between assessment and surgery. Quantification of ER using flow cytometry was performed on the surgically removed tumour samples from tamoxifen-treated (n = 40) and control (n = 38, untreated) patient groups. The tumours were mechanically disaggregated, and saponin treatment rendered these cells permeable to antibodies. Using dual-parameter labelling with a FITC-conjugated antibody (NCL-5D3) directed against cytokeratin 8/18/19 and a biotinylated antibody (DAKO-ER 1D5) directed against the oestrogen receptor, ER quantification was determined on a number of receptors per cell basis. Using QC quantum bead standards, ER levels in the epithelial cell population, the non-epithelial cell population and the whole-cell population (ER+) were calculated. ER levels were significantly lower in the total cell population than tamoxifen-treated patients (P = 0.002) when compared with the control (untreated) group. By using a gating procedure using 5D3 antibody positivity, a significantly lower level was detected on examining the cytokeratin-positive population alone (P = 0.006). Using a complementary gating technique, ER levels were quantified in the cytokeratin-negative cell population. Examination of this group of cells showed no significant difference between the levels of oestrogen receptor found in the tamoxifen-treated and untreated groups (P = 0.4). We have demonstrated that ER levels can be monitored by flow cytometry. ER levels in patients treated with tamoxifen 3 weeks before operation are significantly lower than in a comparative group of patients who received no drug. Furthermore, the most significant difference in receptor levels is seen by quantification of total ER levels expressed by all the tissue. Nature Publishing Group 1998-05 /pmc/articles/PMC2150047/ /pubmed/9635844 Text en https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
spellingShingle Research Article
Brotherick, I.
Browell, D. A.
Shenton, B. K.
Egan, M.
Cunliffe, W. J.
Webb, L. A.
Lunt, L. G.
Young, J. R.
Higgs, M. J.
The effect of 3-week tamoxifen treatment on oestrogen receptor levels in primary breast tumours: a flow cytometric study.
title The effect of 3-week tamoxifen treatment on oestrogen receptor levels in primary breast tumours: a flow cytometric study.
title_full The effect of 3-week tamoxifen treatment on oestrogen receptor levels in primary breast tumours: a flow cytometric study.
title_fullStr The effect of 3-week tamoxifen treatment on oestrogen receptor levels in primary breast tumours: a flow cytometric study.
title_full_unstemmed The effect of 3-week tamoxifen treatment on oestrogen receptor levels in primary breast tumours: a flow cytometric study.
title_short The effect of 3-week tamoxifen treatment on oestrogen receptor levels in primary breast tumours: a flow cytometric study.
title_sort effect of 3-week tamoxifen treatment on oestrogen receptor levels in primary breast tumours: a flow cytometric study.
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2150047/
https://www.ncbi.nlm.nih.gov/pubmed/9635844
work_keys_str_mv AT brothericki theeffectof3weektamoxifentreatmentonoestrogenreceptorlevelsinprimarybreasttumoursaflowcytometricstudy
AT browellda theeffectof3weektamoxifentreatmentonoestrogenreceptorlevelsinprimarybreasttumoursaflowcytometricstudy
AT shentonbk theeffectof3weektamoxifentreatmentonoestrogenreceptorlevelsinprimarybreasttumoursaflowcytometricstudy
AT eganm theeffectof3weektamoxifentreatmentonoestrogenreceptorlevelsinprimarybreasttumoursaflowcytometricstudy
AT cunliffewj theeffectof3weektamoxifentreatmentonoestrogenreceptorlevelsinprimarybreasttumoursaflowcytometricstudy
AT webbla theeffectof3weektamoxifentreatmentonoestrogenreceptorlevelsinprimarybreasttumoursaflowcytometricstudy
AT luntlg theeffectof3weektamoxifentreatmentonoestrogenreceptorlevelsinprimarybreasttumoursaflowcytometricstudy
AT youngjr theeffectof3weektamoxifentreatmentonoestrogenreceptorlevelsinprimarybreasttumoursaflowcytometricstudy
AT higgsmj theeffectof3weektamoxifentreatmentonoestrogenreceptorlevelsinprimarybreasttumoursaflowcytometricstudy
AT brothericki effectof3weektamoxifentreatmentonoestrogenreceptorlevelsinprimarybreasttumoursaflowcytometricstudy
AT browellda effectof3weektamoxifentreatmentonoestrogenreceptorlevelsinprimarybreasttumoursaflowcytometricstudy
AT shentonbk effectof3weektamoxifentreatmentonoestrogenreceptorlevelsinprimarybreasttumoursaflowcytometricstudy
AT eganm effectof3weektamoxifentreatmentonoestrogenreceptorlevelsinprimarybreasttumoursaflowcytometricstudy
AT cunliffewj effectof3weektamoxifentreatmentonoestrogenreceptorlevelsinprimarybreasttumoursaflowcytometricstudy
AT webbla effectof3weektamoxifentreatmentonoestrogenreceptorlevelsinprimarybreasttumoursaflowcytometricstudy
AT luntlg effectof3weektamoxifentreatmentonoestrogenreceptorlevelsinprimarybreasttumoursaflowcytometricstudy
AT youngjr effectof3weektamoxifentreatmentonoestrogenreceptorlevelsinprimarybreasttumoursaflowcytometricstudy
AT higgsmj effectof3weektamoxifentreatmentonoestrogenreceptorlevelsinprimarybreasttumoursaflowcytometricstudy